Patent ID: 7147848

Claim:
A therapeutic method of treating malignant tumors comprising: A. Preparing a recombinant poliovirus from a poliovirus consisting of a 5′NTR region containing an minimal ribosomal entry site (IRES), and the coding sequences for structural proteins (P1), and for the non-structural proteins (P2 and 3) and a 3′NTR, said poliovirus is selected from the group consisting of wild type serotype 1, serotype 2, and serotype 3, by a. substituting at least domain V of the IRES of the poliovirus with at least domain V of the IRES of Human Rhinovirus serotype 2, also having a 5′NTR region containing an internal ribosomal entry site (IRES), the coding sequences for structural protein (P1), and for the non-structural proteins (P2 and P3) and a 3′NTR, b. optionally, substituting P1 of the poliovirus with P1 of a Poliovirus (Sabin), selected from the group consisting of PV1(S), PV2(S) and PV3(S); c. optionally, substituting least 3D pol of P3 of the poliovirus with at least 3D pol of P3 of a Poliovirus (Sabin), selected from the group consisting of PV1(S), PV2(S) an PV3(S); d. optionally, substituting 3′NTR of the poliovirus with 3′NTR of a Poliovirus (Sabin), selected from the group consisting of PV1(S), PV2(S), and PV3(S); and B. Administering intraveneously, intracerebrally, intramuscularly, intraspinally or intrathecally a composition comprising the recombinant poliovirus, wherein the recombinant poliovirus infects and causes cell lysis in the tumor cells.